GeoVax Labs (NASDAQ:GOVX +22.8%) said on Tuesday that the Chinese Patent Office had issued a patent allowance for its cancer vaccine. The claims to be granted by the patent generally cover GeoVax’s vector platform for expressing tumor associated antigens, the company said. It uses GV-MVA-VLP vaccine platform to treat a wide range of cancers, including breast, colon, ovarian, prostate, pancreatic, and lung. The Company recently began an IND-enabling animal study. “This patent allowance complements the previously issued U.S. Patent No. 11278607, demonstrating the global importance of this technology, and adding to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families,” said David Dodd, GeoVax’s CEO.